Jones Trading Remains Bullish on Janux Therapeutics (JANX) Amid Promising Developments in Prostate Cancer Program

Janux Therapeutics, Inc. (NASDAQ:JANX) is 1 of the best small-cap biotech stocks to bargain according to analysts.

On November 11, 2025, Jones Trading’s Soumit Roy reiterated his “Buy” standing connected Janux Therapeutics, Inc. (NASDAQ:JANX), which reflects promising developments successful the company’s prostate crab program. The expert highlighted the company’s mature information from its Phase 1 trials, which is expected to beryllium released successful the 4th fourth of 2025. This includes the company’s innovative T cell-engaging therapies, JANX007 and JANX008. Both therapies person seen important advancement successful the prostate crab space, with JANX007 being tested successful earlier metastatic castration-resistant prostate crab (mCRPC) settings. The full addressable marketplace for these treatments is estimated astatine $10 cardinal successful the U.S. alone.

Soumit Roy besides highlighted the improved efficacy and durability of responses successful the taxane-naïve setting, arsenic shown done the promising preliminary information from JANX007. The analyst’s assurance was besides boosted by Janux Therapeutics, Inc.’s (NASDAQ:JANX) steadfast currency equilibrium of $989 cardinal arsenic of the extremity of the 3rd quarter.

Janux Therapeutics, Inc. (NASDAQ:JANX) reported its Q3 results connected November 7, 2025, signaling a nett nonaccomplishment of $24.3 million, an betterment from $28.1 cardinal successful Q3 2024. The 4th marked beardown momentum successful its Phase 1 trials for its pb candidates, including T cell-engaging therapies, with preliminary information indicating enhanced efficacy and durability of responses. The institution demonstrated disciplined outgo absorption during the quarter, signaling a simplification successful wide and administrative expenses contempt an summation of $34.6 cardinal successful ongoing R&D investment.

Janux Therapeutics, Inc. (NASDAQ:JANX), a clinical-stage biopharmaceutical company, develops caller immunotherapies utilizing its proprietary TRACTr and ARM platforms.

While we admit the imaginable of JANX arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 7 Best Oil and Gas Penny Stocks to Buy According to Analysts and Billionaire Jacob Rothschild’s RIT Capital Partners: 9 Stocks with Huge Upside Potential.

Disclosure: None.